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Several instruments implementing spatially resolved near-infrared spectroscopy (NIRS)
to monitor tissue oxygenation are now approved for clinical use. The neonatal brain is
readily assessible by NIRS and neurodevelopmental impairment is common in children
who were in need of intensive care during the neonatal period. It is likely that an
important part of the burden of this handicap is due to brain injury induced by hypoxia–
ischaemia during intensive care. In particular, this is true for infants born extremely
preterm. Thus, monitoring of cerebral oxygenation has considerable potential beneﬁt
in this group. The beneﬁt, however, should be weighed against the disturbance to
the infant, against the limitations imposed on clinical care and against costs. The
ultimate way of demonstrating the ‘added value’ is by a randomized controlled trial.
Cerebral oximetry must reduce the risk of a clinically relevant endpoint, such as death or
neurodevelopmental handicap. We estimate that such a trial should recruit about 4000
infants to have the power to detect a reduction in brain injury by one-ﬁfth. This illustrates
the formidable task of providing ﬁrst-grade evidence for the clinical value of diagnostic
methods. Is it a window of opportunity for the establishment of a rational basis before
another technology is added to an already overly complex newborn intensive care?
Keywords: near-infrared spectroscopy; preterm; brain; cerebral oxygenation;
neurodevelopmental impairment; randomized controlled trial
1. Clinical research using near-infrared spectroscopy in newborn infants
The ﬁrst clinical research use of near-infrared spectroscopy (NIRS) was seen in
newborn infants and was published in 1985. NIRS was rapidly called ‘promising’
because the newborn brain is readily accessible by NIRS owing to the thin
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scalp and skull of infants. Over the following 25 years, NIRS has contributed
substantially [1] to the pathophysiological background of clinical neonatology.
The question of whether the time has come to put NIRS into clinical neonatal
practice remains.
2. Cerebral oximetry
NIRS allows direct measurement of brain oxygenation, cerebral oximetry, every
second (real-time monitoring). This can be performed in a number of ways as
reviewed elsewhere [2]. Cerebral oxygenation is expressed as a percentage (from
0% to 100%) and represents the haemoglobin–oxygen saturation in all sections of
the vasculature and therefore is ‘venous weighted’. Cerebral oxygenation serves
as a surrogate measure of cerebral blood ﬂow and a direct indicator of brain
ischaemia/hyperaemia as it represents the balance between blood ﬂow and oxygen
requirement. Cerebral oximetry has already been used extensively for research in
newborn infants and in neonatal cardiac care [3].
3. Cerebral oximetry in clinical practice
One retrospective [4] and two randomized controlled trials [5,6] have examined the
clinical value of cerebral oximetry during cardiac surgery and cardiopulmonary
bypass. Although the result is not entirely clear, there is good evidence of a
relation between cerebral hypoxia and post-operative complications and some
indication of improved outcome in patients managed with access to cerebral
oximetry readings. Thus, it is not surprising that such monitoring has been
recommended [7]. Several instruments that provide oximetry are approved for
clinical use and they are entering operating rooms and cardiac intensive care
units.
4. The case for clinical use in neonatology
Newborn infants suffer from a wide range of cardiopulmonary complications
related to pulmonary immaturity, birth injury and malformations that may
compromise oxygenation and/or circulation.
In view of this, it is a problem that the blood pressure is of limited value
as a clinical guide to treatment [8]. Although echocardiography can provide a
wealth of data relevant to the intensive care of extremely preterm infants [9]
and can be repeated as often as necessary, it is a formidable task to provide
reliable echocardiography services on demand in all neonatal intensive care
units. Additionally, the positive predictive value of the echocardiographically
determined state of low circulatory ﬂow in predicting brain injury is low [10]
and interventions aimed at preventing states of low ﬂow have not been shown
to reduce brain injury. Currently, there is no method for monitoring organ blood
ﬂow suitable for clinical needs [11]. Therefore, cerebral oximetry is a candidate for
a breakthrough diagnostic tool needed for the clinical management of circulatory
insufﬁciency in the newborn.
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5. The special case: the extremely preterm infant shortly after birth
The cardiovascular transition at birth is a particularly serious challenge for infants
born more than 12 weeks preterm—called extremely preterm. In a preterm infant,
immature lung function impedes the recruitment of the vascular bed of the
lungs and the closure of the arterial duct is delayed. The immature myocardium
has limited systolic and diastolic function and, as a result, regulation of organ
blood ﬂow is weak and vulnerable [12]. Currently, extremely preterm infants
have an average mortality of 20 per cent [13] and approximately 10 per cent of
survivors develop cerebral palsy and 25 per cent of survivors grow up with either
cerebral palsy or low intelligence quotient. Such neurodevelopmental impairment
is a major cause of reduced quality of life as well as increased medical care,
rehabilitation and special education costs in this population.
There is a high risk of neurodevelopmental impairment in extremely preterm
infants that can be caused by several types of brain injury and subsequent
disturbance of brain development [14]. One important mechanism is hypoxia–
ischaemia [15]; another is hyperoxia [16]. Hypoxia–ischaemia of the central white
matter of the immature brain is often complicated by severe brain haemorrhage
[17]. These haemorrhages are typically preceded by episodes of low blood pressure
[18], low cardiac output [19] and low cerebral blood ﬂow during the ﬁrst 24 h
following birth [20]. Thus, circulatory insufﬁciency during the ﬁrst few days of life
is a root cause of brain injury in extremely preterm infants and cerebral oximetry
during these ﬁrst critical days could potentially make a very signiﬁcant difference.
6. The arguments against starting to use cerebral oximetry in extremely
preterm infants
The extremely preterm infant is small with fragile skin. Placing a probe on the
head and maintaining its position is another challenge for nurses, and it interferes
with the already compromised bonding between parents and infant (ﬁgure 1). It
must have a clear beneﬁt.
Cerebral oximetry during surgery is partly based on the use of trends, i.e.
comparing the current value with the value before anaesthesia when the patient
was awake, or at least before some critical manoeuvre, such as clamping of an
artery. This in general does not make sense in the extremely preterm infant after
birth. It cannot be assumed that any particular moment after stabilization of
respiration and postnatal circulation can be used as a reference point.
It is therefore a speciﬁc limitation of the current commercial NIRS oximeters
that the absolute level of oxygenation is relatively poorly determined. Reliability
of the measurement compared with oxygen saturation in jugular venous blood is
8–9%. This corresponds to the limits of agreement ranging from −17 to +17 per
cent [21]. While this may be sufﬁcient for the detection of gross abnormality [22],
such abnormalities are likely to be relatively rare and may often be detected by
other means. More generally, these infants are already monitored and are under
close clinical supervision, and, while existing means of judging the circulatory
sufﬁciency are not ideal, they are not without value. Thus, the key question
is whether cerebral oximetry adds signiﬁcantly to the total clinical picture, i.e.
whether cerebral oximetry has added diagnostic value.
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Figure 1. An infant shortly after birth born at 25 weeks of gestation. The tube for artiﬁcial
ventilation passes through the nose to the trachea and is ﬁxed to the skin with tape. The skin
is fragile; hence this is acceptable only because ventilation is lifesaving. The cap covering the head
and the sheet covering the body are partly to conserve heat, partly for the comfort of the baby,
and partly to emphasize the dignity and individuality of the infant. In this context, the practical
problem of applying a new probe for monitoring is a signiﬁcant concern. (Online version in colour.)
It is necessary to have reference values in order to diagnose cerebral hypoxia
(or hyperoxia). Animal experimentation shows that cerebral oxygenation has to
decrease to 35 per cent before electrical failure occurs, and that neuronal injury
occurs if the low value persists for several hours [23,24].
For a diagnosis to be useful to the patient and improve clinical outcome,
it is necessary that effective treatment is available. In some contexts, this is
very likely to be the case for extremely preterm infants. Inadvertent mechanical
hyperventilation induces cerebral vasoconstriction and decreased cerebral blood
ﬂow [25]. Inadvertent hyperventilation is strongly associated with cerebral white
matter damage and cerebral palsy in surviving preterm infants [15]. Monitoring of
the arterial carbon dioxide concentration by the transcutaneous route is possible,
but not easy, and is therefore not universally used. Cerebral oximetry is likely to
be an effective means of avoiding this problem simply by prompting the clinician
to reduce ventilatory support. On the other hand, a state of low cardiac output is
also common in extremely preterm infants [19]. Low cardiac output has signiﬁcant
long-term consequences [26] but it is difﬁcult to treat [27].
A state of cerebral hypoxia will lead the clinician to consider allowing the
arterial pCO2 to increase, to use vasopressors to increase the arterial blood
pressure, to use volume transfusion or inotropes to increase the cardiac output,
to give a red blood cell transfusion to increase blood haemoglobin and to increase
the inspired oxygen concentration to increase arterial oxygen saturation.
A state of cerebral hyperoxia, on the other hand, may lead the clinician to
attempt to reduce the arterial pCO2 or reduce the inspired oxygen fraction.
Hyperoxygenation, oxygen toxicity and free oxygen radical damage are also
implicated in brain white matter injury in extremely preterm infants [14].
Finally, cost is a signiﬁcant concern. Healthcare services are stressed by
increasing demands, increasing technical possibilities and increasing costs. Public
or private, the resources used for healthcare cannot be used for other signiﬁcant
purposes, such as education, social security, protection of the environment
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and local, national or global law and justice. These are all important factors
for the future of children. This emphasizes the need to be concerned with
cost-effectiveness.
7. The case for formal evaluation of the clinical beneﬁt of cerebral oximetry
in extremely preterm infants
Although all of the interventions described above have considerable pathophysio-
logical rationality, they also have side-effects and may have unforeseen effects in a
complex clinical context. On the other hand, a ‘reassuring’ reading of the cerebral
oximeter may allow the clinician to defer an intervention that also has costs and
may also have unwanted side-effects. Therefore, the only way to make sure that
cerebral oximetry does more good than harm is to test it in combination with a
physiology-based treatment guideline (ﬁgure 2).
Several measures of success can be deﬁned. First, is it possible to reduce the
amount of time spent with cerebral oxygenation out of target range? Second,
is it possible to reduce molecular or electroencephalographic markers of acute
hypoxic–ischaemic brain injury? Third, is it possible to reduce brain damage as
determined by ultrasound or magnetic resonance imaging when the infant reaches
term age and is ready to be discharged home? Finally, is it possible to reduce the
risk of neurodevelopmental deﬁcit as the child grows up? Although the ﬁrst three
measures are relevant, and even can be mechanistically necessary intermediate
steps, it is only the last measure that is truly clinically meaningful.
8. A randomized controlled trial
The gold standard method for evaluating the clinical beneﬁts of medical
interventions is the randomized controlled trial. Apart from randomization, this
methodology is based on strict inclusion and exclusion criteria on a single
prespeciﬁed primary ‘endpoint’, and on a sample size that is able to exclude a
minimal clinically relevant difference in this endpoint between the experimental
and the control groups. This means that the trial should be able to give statistical
support for a clinically relevant effect size.
9. Outline of a trial in extremely preterm infants testing the effect of cerebral
oximetry on neurodevelopment at 2 years of age
Entry criteria will be hospital-born, more than 12 weeks preterm, a clinical
decision of full life support and parental informed consent. The monitoring by
cerebral oximeter must be started before 3 h of age. To detect a difference of ﬁve
points in the primary outcome (s.d. 15 points) with a chance of 90 per cent at the
5 per cent signiﬁcance level, it is necessary to have outcome data on 190 infants
in each group (ﬁgure 3). As mortality in these infants is as high as 20 per cent,
randomization of 250 infants to each intervention group is needed.
This plan, however, assumes that cerebral oximetry may have no effect on
mortality. Although it is not predicted that monitoring the brain and optimizing
brain oxygenation will change mortality, this is not certain. Therefore, mortality
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establishment of monitoring:
as soon as possible, usually after pulse oximetry but before placement of
intravascular access
period of monitoring:
clinical management options:
48 h
(i)
(ii)
(iii)
(iv)
(v)
(vi)
(vii)
(viii)
(ix)
(i)
(ii)
(iii)
values <55% (cerebral hypoxia)
values >85% (cerebral hypoxia)
haemodynamically significant PDA: medical closure
low mean blood pressure (<GA in weeks): vasopressor
capillary refill time >3 s: normal saline
on CPAP/PEEP: decrease pressure
on mechanical ventilation with pCO2 values below 30 mm Hg (4 kPa):
on mechanical ventilation with pCO2 >60 mm Hg (8 kPa): increase
minute ventilation
reduce minute ventilation
Hb <8.0 mmol l–1 (13 g%): give red blood cells
SaO2 <85%: increase FiO2
lactate >3.5 mmol l–1 and high vasopressors: reduce vasopressors
exclude congenital heart disease
SaO2 >92%: reduce FiO2
blood glucose <2.5 mmol l–1: increase glucose intake
the cerebral oxygenation target range is 55–85%. If out of range,
then choose one or more interventions listed below. Reassess after 30 min 
Figure 2. A clinical management guideline using cerebral oxygenation from the brain to improve
the clinical care of extremely preterm infants during the ﬁrst 48 h after birth. Many aspects of
neonatal intensive care are involved. Although the guideline reﬂects a large body of knowledge of
pathophysiology in the newborn brain, some of the interventions have not been shown directly to
improve cerebral oxygenation. The guideline was developed during the planning of a randomized
controlled trial by a European Academic Consortium with partners from Copenhagen, Utrecht,
Leuven, Madrid, Zurich, Uppsala, Milan, Graz, Cambridge, Witten/Herdecke, Lyon and Cork.
CPAP, continuous positive airway pressure; GA, gestational age; HB, haemoglobin; PDA, patent
ductus arteriosus; PEEP, positive end-expiratory pressure.
should be included in the primary endpoint, and most randomized controlled
trials on early interventions in extremely preterm infants actually do have a
combined endpoint, such as death or neurodevelopmental impairment. As the
risk of neurodevelopmental impairment is 25 per cent and a reasonable beneﬁt
of cerebral oximetry to be hoped for would be a reduction to 20 per cent, the
number needed to be randomized will be 4100 infants.
10. Is an adequately powered randomized controlled trial feasible?
Many neonatologists have great expectations for cerebral oximetry at the
present time and are prepared to start moving. At the same time, there is
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Figure 3. Calculation of sample size for a randomized controlled trial to demonstrate the clinical
beneﬁt of cerebral oximetry in extremely preterm infants. It is hoped that the risk of brain
injury can be reduced and it is expected that this will result in improved cognitive development.
Calculations are based on an effect size of ﬁve points, corresponding to a Cohen d of 0.33, as the
standard deviation of a test measuring cognitive function is 15 points, and a study power of 90%. It
can be seen that 190 infants will be needed in each of the groups and that the groups must be even
larger if the effect size is less, or if the study power should be higher. (Online version in colour.)
sound scepticism, as neonatology is a clinical ﬁeld with a history of signiﬁcant
iatrogenic epidemics. The best known examples are oxygen-induced retinopathy
and postnatal steroid-induced cerebral palsy. Therefore, a well-constructed and
well-conducted randomized clinical trial could help to promote the ﬁeld of
cerebral monitoring in a rational way. It is feasible, as 25 000 extremely preterm
infants are born in Europe alone every year. It is evident, however, that an
open-label trial of a several-day-long intervention is difﬁcult to carry out well.
Furthermore, a reduction in cerebral oxygenation outside the target range can
only be achieved if the treatment guideline is efﬁcient. A reduction in brain injury
will be achieved only if the target range is physiologically meaningful, and if
hypo- or hyperoxygenation in the ﬁrst days of life constitutes a signiﬁcant aetio-
logical fraction. Finally, a reduction in neurodevelopmental deﬁcit will be achieved
only if other kinds of brain injury are not increased by the intervention.
11. Can instrumentation be improved for the extremely preterm infant?
The precision of current instruments is only 4–6% [28,29]. In the case of extremely
preterm infants, the brain is immature and the cerebrospinal ﬂuid space is
wide in some regions (ﬁgure 4). This may lead to severe deviations from the
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sylvian
5 cm
parieto-occipital
Figure 4. Magnetic resonance image of the brain shortly after birth in an infant born at 25 weeks
of gestation. The brain is immature with few sulci and gyri. The thickness of both the skin and
skull is 3–4mm each. The sylvian ﬁssure is widely open, and there is a large cerebrospinal ﬂuid
space in the parieto-occipital region. The ﬂuid spaces constitute signiﬁcant optical inhomogeneities
for near-infrared spectroscopy, because photons can travel far with little chance of absorption or
scattering. The result can be large differences in the values of cerebral oxygenation depending
on the exact positioning of the source and the detector (MR images courtesy of M. Rutherford,
Imperial College, London, UK).
assumption of optic homogeneity in terms of scatter and absorption and this
in turn may signiﬁcantly disturb the calculation of tissue oxygenation (StO2).
One way to address this problem is to use multiple pathways, and such a probe is
shown in ﬁgure 5. This design reduced the imprecision of measurement (measured
as reproducibility of multiple re-settings of the probe on the head of preterm
newborns) to 2.7 per cent [30].
(a)Minimal source–detector separation: Monte Carlo simulations
Simulations were performed to search for a minimally reliable source–detector
distance using a simple two-layer slab geometry, i.e. the skin/scalp layer and the
brain. The optical and physiological parameters were those typical of a neonate
with a gestational age of 30–31 weeks. It is known that the StO2 measurement
based on spatially resolved spectroscopy (SRS) [31] is inﬂuenced by both the
skin/scalp layer and the brain layer but to a different extent. Seven designs were
analysed. They are based the distances of separation between one detector and
two sources (table 1).
From ﬁgures 6 and 7, we concluded that it appears to be possible to use shorter
distances in the extremely preterm infant brain than those used by current general
purpose instruments, and yet obtain a good compromise for the probe size, the
sensitivity to the brain and the robustness against SO2 changes in the skin/scalp.
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detector light path
Figure 5. The layout of a probe with four sources and two detectors allowing simultaneous
measurement of StO2 from four adjacent brain areas. This design may be used for imaging purposes;
for the purpose of intensive care, the mean value of StO2 may be used as a global mean. It is less
susceptible to imprecision owing to tissue heterogeneity compared with recording from a single
brain area. Furthermore, the agreement among the four measures may be used to indicate the
reliability of the mean value at any given time. (Online version in colour.)
Table 1. Source–detector separation used for the Monte Carlo simulation, each set represents a
potential design for an NIRS sensor optimized for the preterm newborn brain (see ﬁgure 5).
design distance c (cm) distance d (cm)
1 0.7 1.1
2 0.8 1.3
3 1.1 1.8
4 1.3 2.0
5 1.5 2.5
6 2.0 3.0
7 2.5 3.5
12. What are the alternatives?
Very few examples of diagnostic methods exist where the clinical beneﬁt has
been demonstrated in randomized trials. Most diagnostic methods are part of
a more or less complex clinical context where gradual progress occurs over time
Phil. Trans. R. Soc. A (2011)
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Figure 6. Simulated StO2 in a two-layer geometry as a function of brain SO2. The SO2 in the
skin/skull layer was ﬁxed at 70%. All results deviate from the true brain value. The discrepancy
is expected for two main reasons. The ﬁrst is that the spatially resolved spectroscopy (SRS)-based
StO2 algorithm ignores the effect of water. The second reason is that the SRS algorithm is based
on the assumption of a homogeneous semi-inﬁnite half-space geometry. All designs are responsive
to changes in brain SO2. Designs 1 and 2 underread greatly, whereas the designs with larger
source–detector distance all produced similar results. (Online version in colour.)
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Figure 7. The sensitivity of the seven designs against SO2 changes in the skin/scalp layer as
indicated by the vertical bars. Brain SO2 was ﬁxed at 70% while the skin/scalp SO2 was varied
between 50% and 90%. Simulated StO2 values from the two-layer geometry are inﬂuenced by the
changes in the skin/scalp layer. In particular, designs 1 and 2 are not robust. (Online version in
colour.)
with improving clinical outcomes. The technologies are exposed to the economical
pressure of competition of providers and the competition of alternative use of
healthcare resources.
On the one hand, cerebral oximetry can potentially become inexpensive as
it is based on technology that can be mass produced. Also, the probe may be
miniaturized and integrated with the electronics into a soft ‘plaster’ that may stick
to the skin of the head of tiny infants and need little attention. Solid evidence of
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beneﬁt to patients will create a large market. Evidence of beneﬁt of an instrument
using public domain technology can serve as a platform for healthy competition
on user-friendliness and price.
On the other hand, what will happen if the clinical use of cerebral oximetry is
not developed in a rational, evidence-based format? Then it may become another
randomly applied expensive technology. Cerebral oximetry will be supported
by anecdotal evidence, expert opinion, active branding and marketing. The
consequences include unnecessary disturbances and risks to a very vulnerable
group of patients and depletion of scarce healthcare resources.
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